STUDY

Rinvoq cleared eczema in more adults than Dupixent by week 16

“Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.” Blauvelt A et al. JAMA Dermatology. September 2021

Blauvelt A et al. · JAMA Dermatology · September 2021

Phase 3b randomized controlled trial
The finding

In the corrected Heads Up analysis, 72.4% on upadacitinib and 62.6% on dupilumab had at least a 75% drop in their eczema score by week 16.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. Everyone received both pills and injections, with only one active drug. The corrected analysis excludes 19 participants from one site.
At a glance

Who was studied and for how long

Analyzed
673 adults
After the published correction
Length
24 weeks
Main result at week 16
Condition
Moderate to severe eczema
Eligible for systemic treatment
Compared
Pill vs injection
Upadacitinib vs dupilumab
What they did

How the study worked

673 adultscorrected analysisRANDOMSPLITUpadacitinib342 analyzed30 mg dailyDupilumab331 analyzed300 mg every 2 weeksMEASURED ATWeek 16main eczema score673 adultscorrected analysisRANDOMSPLITUpadacitinib342 analyzed · 30 mg dailyDupilumab331 analyzed · 300 mg every 2 weeksMEASURED ATWeek 16main eczema score
Random assignmentThe study assigned adults to upadacitinib or dupilumab.
Two routesOne group took 30 mg of upadacitinib daily. The other received 300 mg of dupilumab every two weeks after a 600 mg starting dose.
Eczema scoringThe primary outcome was a drop of at least 75% in EASI by week 16.
What they found

The results

UpadacitinibDupilumab

At least 75% improvement at week 16

Share who reached EASI 75 in the corrected analysis.

Upadacitinib
72.4%
Dupilumab
62.6%
p = 0.007

Completely clear on the eczema score at week 16

Share who reached EASI 100, a secondary outcome.

Upadacitinib
28.4%
Dupilumab
7.9%
p < 0.001
More people on upadacitinib reached the main goal at week 16. At week 24 the EASI 75 gap was smaller (65.3% vs 61.2%; unadjusted p = 0.29). Serious infections and shingles were reported more often with upadacitinib; conjunctivitis and injection-site reactions were more frequent with dupilumab.
Who paid for it

Funding and conflicts of interest

AbbVie funded the study and participated in the design, analysis and reporting. Several authors were AbbVie employees.

How much to trust it

Strengths and limits

Strengths

  • Large blinded comparison across multiple countries
  • Direct comparison with another active treatment
  • Measured skin improvement, itch and adverse events

Limits

  • The main result was at week 16, with follow-up through week 24
  • Only adults and one upadacitinib dose were studied
  • The trial cannot settle differences in rare or long-term harms
  • One site was excluded from the corrected analysis
High confidence in the week 16 comparison. The large blinded trial supports the short-term result; it cannot determine which treatment is safer long term.
What it means for you

The takeaway

More early improvement

More adults on upadacitinib reached the week 16 skin goal, and the two medicines had different side effects.

The trial did not compare the 15 mg upadacitinib dose with dupilumab.

Terms in this study

Words worth knowing

EASI

A score based on the area of skin affected and the severity of eczema signs.

EASI 75

At least a 75% reduction in the EASI score.

EASI 100

No eczema signs left on the EASI score.

Conjunctivitis

Inflammation of the tissue that lines the eyelid and covers the white of the eye.

Original source

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.. JAMA Dermatol. 2021;157(9):1047-1055.

PMID 34347860